Neobiomics, a Swedish life science company focused on improving outcomes for preterm infants through evidence-based nutritional products, has received an investment led by HealthCap, a specialist provider of life sciences venture capital in Europe.
“HealthCap brings deep life science expertise, a strong international network, and extensive experience in building global life science companies,” said Emma Höglund, CEO of Neobiomics. “This investment is an important milestone for Neobiomics and supports our ambition to bring evidence-based neonatal solutions to more infants worldwide.”
HealthCap’s investment will support Neobiomics’ commercial expansion, international growth, and further development of its portfolio within neonatal and pediatric health.
“With HealthCap onboard, we are well positioned to accelerate our international growth and continue building a leading company within neonatology” said Stefan Johansson, co-founder and chair of Neobiomics.
In conjunction with the investment, Mårten Steen, managing partner at HealthCap, will join the board.
“The unmet medical need in neonatal care remains significant – outcomes for the most vulnerable newborns depend on earlier, more accurate intervention,” said Steen. “Neobiomics is addressing this gap with a compelling and differentiated portfolio, backed by strong clinical evidence and a proven commercial presence.”
Press release: HealthCap invests in Neobiomics to support continued growth in neonatal care – Neobiomics